Symbol | Exchange | Currency |
|---|
Investing.com - Zealand Pharma (NASDAQ:ZEAL) ADR reported on Thursday second quarter earnings that missed analysts' forecasts and revenue that fell short of expectations. ...
Needham & Company analyst Joseph Stringer reiterated a Buy rating and $32.00 price target on Zealand Pharma A/S (NASDAQ:ZEAL), as the company reported positive Phase 3 results...
Zealand Pharma A/S (NASDAQ:ZEAL) announced that it has initiated the second phase III study to evaluate its pipeline candidate, dasiglucagon, in pediatric patients with...
As of late, it has definitely been a great time to be an investor Zealand Pharma A/S (NASDAQ:ZEAL) . The stock has moved higher by 2.9% in the past month, while it is also above...
The biotech sector saw updates from a few bigwigs last week. Both Regeneron (NASDAQ:REGN) and Biogen (NASDAQ:BIIB) obtained positive opinions on their drugs from the CHMP....
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company’s pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Buy | Buy | Buy | Sell |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Strong Sell | Strong Sell |
| Summary | Strong Buy | Strong Buy | Strong Buy | Neutral | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 194.70 | 194.76 | 180.63 | +13.87 | +7.67% | 107.34M | NASDAQ | |||
| 305.53 | 308.26 | 280.41 | +24.57 | +8.74% | 15.78M | NASDAQ | |||
| 26.21 | 26.23 | 24.91 | +0.61 | +2.38% | 3.64M | NYSE | |||
| 1,626.96 | 1,634.74 | 1,553.00 | +74.24 | +4.78% | 441.30K | NYSE | |||
| 16.50 | 16.62 | 16.19 | +0.41 | +2.55% | 33.39M | NYSE | |||
| 9.59 | 9.63 | 9.05 | +0.41 | +4.47% | 7.45M | NASDAQ | |||
| 13.90 | 13.95 | 13.45 | +0.15 | +1.09% | 59.45M | NYSE | |||
| 175.84 | 176.66 | 162.61 | +11.15 | +6.77% | 3.58M | NASDAQ | |||
| 62.21 | 62.34 | 59.38 | +2.59 | +4.34% | 4.38M | NASDAQ | |||
| 551.03 | 551.66 | 517.83 | +29.64 | +5.68% | 4.54M | NASDAQ | |||
| 148.03 | 148.72 | 140.55 | +6.86 | +4.86% | 106.46M | NASDAQ | |||
| 16.32 | 16.44 | 15.87 | +0.45 | +2.84% | 25.22M | NYSE | |||
| 108.37 | 108.43 | 103.75 | +2.87 | +2.72% | 126.45K | NASDAQ | |||
| 77.25 | 77.25 | 74.38 | +2.40 | +3.21% | 6.69M | NYSE | |||
| 84.70 | 84.90 | 82.06 | +2.21 | +2.68% | 8.96M | NYSE |